Compare BioNano Genomics Inc (BNGO) vs First Solar, Inc. (FSLR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs First Solar, Inc. — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.77M), while First Solar, Inc. trades at $223.55 (market cap $25.89B). The key difference: First Solar, Inc. is far larger — about 1880.2× BioNano Genomics Inc's market cap, and First Solar, Inc. is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | FSLR | |
|---|---|---|
Market Cap | $13.77M | $25.89B |
Sector | Health | Technology |
52-Week High | $4.92 | $318.30 |
52-Week Low | $1.06 | $180.05 |
Enterprise Value | $16.38M | $24.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.18, down 0.84% today, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company shows improving financial trends, with net losses narrowing significantly from -$232M in 2023 to -$26M in 2025, and recent earnings beats. Revenue remains steady around $29M, while analyst sentiment is positive with 57% buy ratings.
Outlook: BNGO presents a speculative opportunity with strong analyst support and improving fundamentals, but risks include persistent negative cash flows, high operating costs, and competitive pressures in genomics. The stock's low valuation multiples may attract value investors, yet profitability remains a key hurdle.
First Solar (FSLR) trades at $223.69, down 7.15% amid a class action lawsuit alleging securities fraud from February 2025 to February 2026. Technically, the stock is bearish with support at $215 and resistance at $228. Fundamentally, revenue grew to $5.22B in 2025 with a net income margin of 29.27%, though Q4 2025 EPS missed expectations. Analyst consensus is bullish with a $282.07 price target, but legal risks cloud near-term sentiment.
The outlook is mixed: strong profitability and growth support upside, but the lawsuit and bearish technicals pose risks. Investors should weigh robust fundamentals against legal uncertainties and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →
